168 related articles for article (PubMed ID: 31366633)
1. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
2. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
[TBL] [Abstract][Full Text] [Related]
3. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
4. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
[TBL] [Abstract][Full Text] [Related]
5. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
[TBL] [Abstract][Full Text] [Related]
6. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Xu Y; Wu W; Wang L; Chintala M; Plump AS; Ogletree ML; Chen Z
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
[TBL] [Abstract][Full Text] [Related]
7. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
8. Influence of bivalirudin on tissue factor-triggered coagulation.
Butenas S; Orfeo T; Brummel-Ziedins KE; Mann KG
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):407-14. PubMed ID: 17581314
[TBL] [Abstract][Full Text] [Related]
9. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Bates SM; Weitz JI
Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
[TBL] [Abstract][Full Text] [Related]
10. A screening procedure to evaluate the anticoagulant activity and the kinetic behaviour of direct thrombin inhibitors.
Rupin A; Mennecier P; de Nanteuil G; Laubie M; Verbeuren TJ
Thromb Res; 1995 May; 78(3):217-25. PubMed ID: 7631302
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin effects of native and recombinant hirudins.
Markwardt F; Stürzebecher J; Glusa E
Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
[TBL] [Abstract][Full Text] [Related]
12. Bivalent direct thrombin inhibitors: hirudin and bivalirudin.
Warkentin TE
Best Pract Res Clin Haematol; 2004 Mar; 17(1):105-25. PubMed ID: 15171961
[TBL] [Abstract][Full Text] [Related]
13. Immobilization of the direct thrombin inhibitor-bivalirudin on 316L stainless steel via polydopamine and the resulting effects on hemocompatibility in vitro.
Lu L; Li QL; Maitz MF; Chen JL; Huang N
J Biomed Mater Res A; 2012 Sep; 100(9):2421-30. PubMed ID: 22566466
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic and Clot-Based Bivalirudin Assays for Monitoring Anticoagulation.
Raghavendran P; Tillman BF; Wheeler AP; Gailani D
J Appl Lab Med; 2023 Nov; 8(6):1074-1083. PubMed ID: 37811688
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
[TBL] [Abstract][Full Text] [Related]
16. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.
Gosselin RC; King JH; Janatpur KA; Dager WH; Larkin EC; Owings JT
Arch Pathol Lab Med; 2004 Oct; 128(10):1142-5. PubMed ID: 15387708
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide.
Römisch J; Stöhr HA; Stauss H; Koschinsky R; Stüber W; Pâques EP
Thromb Haemost; 1994 Mar; 71(3):320-4. PubMed ID: 8029796
[TBL] [Abstract][Full Text] [Related]
18. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
19. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Callas DD; Hoppensteadt D; Fareed J
Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
